Patritumab Antibody

SKU: orb1980647

Description

Patritumab (U3-1287) is a human monoclonal antibody targeting HER3, which exerts antitumor effects by inhibiting the phosphorylation of HER3, EGFR, HER2, ERK, and AKT pathways. It has demonstrated the ability to induce apoptosis and suppress proliferation in non-small cell lung cancer models in both in vitro and in vivo studies.

Research Area

Cardiovascular Research, Cell Biology, Epigenetics & Chromatin, Molecular Biology, Signal Transduction

Key Properties

• CAS Number: 1262787-83-6
• MW: 146.97 kDa
• Purity: 98.2% (SEC-HPLC)
• Target: Survivin,Akt,HER,PARP,ERK,EGFR

Bioactivity

• In Vivo:
  In a DiFi-HRG tumor xenografts model in mice, Patritumab (1 mg/mouse; intraperitoneal; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity. Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and combination therapy with cetuximab and patritumab overcomes such resistance in vivo.
• In Vitro:
  Patritumab targets the extracellular domain (ECD) of HER3 and induces apoptosis in DiFi-HRG4 cells (10 μg/mL; 5 days). Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT in DiFi-HRG4 cells without affecting that of ERK. Additionally, Patritumab (10 μg/mL; 48 h) induces the cleavage of PARP, accompanied by both up-regulation of BIM and down-regulation of survivin expression.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

U3-1287, ERK, EGFR, HER, AMG-888, Akt

Quick Database Links

Gene Symbol

Survivin,Akt,HER,PARP,ERK,EGFR